Published on 28 Dec 2023 on Zacks via Yahoo Finance
Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug
Shares of Iovance Biotherapeutics, Inc. IOVA were down 18.7% on Dec 27 after the company announced a clinical update on its tumor infiltrating lymphocyte ("TIL") therapy, LN-145, in the non-small cell lung cancer (“NSCLC”) indication.
The phase II IOV-LUN-202 study is currently evaluating LN-145 for treating patients who have progressed on or after chemotherapy and anti-PD-1 therapy for advanced (unresectable/metastatic) NSCLC.
On Dec 22, 2023, the FDA placed a clinical hold on the IOV-LUN-202 study following a grade 5 (fatal) serious adverse effect, potentially related to the non-myeloablative lymphodepletion pre-conditioning regimen observed in the study.